ALLO (Allogene Therapeutics) 6-Month Price Index : 0.72 (As of Mar. 14, 2025)

View and export this data going back to 2018. Start your Free Trial

What is Allogene Therapeutics 6-Month Price Index?

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2025-03-14), Allogene Therapeutics's 6-Month Price Index is 0.72.

Competitive Comparison of Allogene Therapeutics's 6-Month Price Index

For the Biotechnology subindustry, Allogene Therapeutics's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allogene Therapeutics (NAS:ALLO) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index

Current Share Price

Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allogene Therapeutics (NAS:ALLO) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Allogene Therapeutics 6-Month Price Index Related Terms

Thank you for viewing the detailed overview of Allogene Therapeutics's 6-Month Price Index provided by GuruFocus.com. Please click on the following links to see related term pages.

Allogene Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allogene Therapeutics Inc (NAS:ALLO) » Definitions » 6-Month Price Index

Comparable Companies

Traded in Other Exchanges

N/A

Address

210 East Grand Avenue, South San Francisco, CA, USA, 94080

Website

https://www.allogene.com

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

Executives

Earl Martin Douglas	officer: GENERAL COUNSEL	BIOMIMETIC THERAPEUTICS, INC., 389 NICHOL MILL LANE, FRANKLIN TN 37067
Zachary Roberts	officer: EVP of R&D	C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
David D Chang	director, officer: President and CEO	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Geoffrey M. Parker	officer: CHIEF FINANCIAL OFFICER	15 RIORDAN PLACE, MENLO PARK CA 94025
Timothy L. Moore	officer: Chief Technical Officer	C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Deborah M. Messemer	director	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Franz B Humer	director	388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013
Arie Belldegrun	director, 10 percent owner	UCLA SCHOOL OF MEDICINE, 10833 LE CONTE 66-118 CHS BOX 951738, LOS ANGELES CA 9095-1738
Yinlin Jack Chen	officer: SVP, Finance	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Stephen Mayo	director	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Lillian Smith	officer: VP, Corporate Counsel	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Veer Bhavnagri	officer: General Counsel	C/O ALLOGENE THERAPEUTICS, INC., 210 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Owen N. Witte	director	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Rafael Amado	officer: EVP of R&D and CMO	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Alison Moore	officer: Chief Technical Officer	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080